Medicure publishes investor presentation highlighting US growth strategy for Zypitamag, Aggrastat and Marley Drug pharmacy unit

PUBT · 2d ago
Medicure publishes investor presentation highlighting US growth strategy for Zypitamag, Aggrastat and Marley Drug pharmacy unit
  • Medicure outlined a US-focused strategy built on expanding ZYPITAMAG, AGGRASTAT, and its Marley Drug e-commerce pharmacy platform.
  • Marley Drug revenue totaled CAD 20.3 million in 2025, up 88% year over year; ZYPITAMAG units dispensed rose 17%.
  • ZYPITAMAG revenue was CAD 6.5 million in 2025, up 5% year over year; positioned within a statin market cited at USD 4 billion.
  • AGGRASTAT revenue reached CAD 5.7 million in 2025, up 29% year over year; marketed as the only approved 3.75 mg bolus vial format.
  • Pipeline focus centered on completing a Phase 3 MC-1 study in PNPO deficiency; approval could yield a priority review voucher with recent sales above USD 75 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicure Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.